Recurrence after liver transplantation for hepatocellular carcinoma (HCC) represents an important cause of mortality for this surgical population. In addition to tumor characteristics, It has been suggested that pre-treatment and sirolimus-based immunosuppression may affect recurrence and survival. With data from the European Liver Transplant Registry (ELTR) database, the aim of this study is to investigate the impact of tumor characteristics, pre-transplant treatment and immunosuppression regimens on survival after liver transplantation for HCC.
Study Type
OBSERVATIONAL
Enrollment
23,124
Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
Immunosuppression regimens containing Sirolimus
Overall survival
Time frame: up to 10 year survival
Hepatocellular carcinoma specific survival
Time frame: 5 year and 10 year survival
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.